The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Exploiting the metabolic vulnerabilities of MDS stem cells
Progression from low risk to high risk disease in myelodysplastic syndrome (MDS) remains poorly understood. Daniel Pollyea, MD, MS, University of Colorado, Denver, CO, describes the unique metabolic vulnerabilities of MDS stem cells, which similarly exist in adult acute myeloid leukemia (AML). By elucidating changes in metabolic pathways within different stages of the diseases, new targets can be found that can improve response rates in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
